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Abstract
Gray matter atrophy is an important correlate to clinical disability in multiple sclerosis (MS) and
many treatment trials include atrophy as an outcome measure. Atrophy has been shown to occur in
experimental autoimmune encephalomyelitis (EAE), the most commonly used animal model of
MS. While the clinical severity of EAE is reduced in estrogen treated mice, it remains unknown
whether estrogen treatment can reduce gray matter atrophy in EAE. In this study, mice with EAE
were treated with either estrogen receptor (ER)-alpha ligand or ER-beta ligand, diffusion tensor
images (DTI) were collected and neuropathology performed. DTI showed atrophy in the cerebellar
gray matter of vehicle-treated EAE mice as compared to healthy controls, but not in ER-alpha or
ER-beta ligand-treated EAE mice. Neuropathology demonstrated that Purkinje cell numbers were
decreased in vehicle-treated EAE mice, while neither ER ligand-treated EAE groups showed a
decrease. This is the first report of a neuroprotective therapy in EAE that unambiguously prevents
gray matter atrophy while sparing a major neuronal cell type. Fractional anisotropy (FA) in the
cerebellar white matter was decreased in vehicle-and ER-beta ligand-treated, but not in ER-alpha
ligand-treated EAE mice. Inflammatory cell infiltration was increased in vehicle-and ER-beta
ligand-treated, but not in ER-alpha ligand-treated EAE mice. Myelin staining was decreased in
vehicle-treated EAE mice, and spared in both ER ligand-treated groups. This is consistent with
decreased FA as a potential biomarker for inflammation rather than myelination or axonal damage
in the cerebellum in EAE.
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INTRODUCTION
Magnetic resonance imaging (MRI) measures of gray matter atrophy are an important
characteristic of many neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s
disease and multiple sclerosis (MS). In fact, there is a strong link between gray matter
atrophy and disability in all of these diseases (Camicioli et al. 2003; Chard et al. 2002;
Firbank et al. 2007). Whole brain atrophy was described in MS over a decade ago (Rudick et
al. 1999) and several studies have since demonstrated a strong relationship between gray
matter atrophy and disability (Amato et al. 2008; Calabrese et al. 2010; Ge et al. 2000).
Indeed, gray matter atrophy is considered to be one of the most clinically relevant markers
of MS disease progression (Bermel and Bakshi 2006; Fisher et al. 2002; van den Elskamp et
al. 2010).
Diffusion tensor imaging (DTI) measures the diffusion of water molecules. When the
mobility of a water molecule is not the same in all directions, its diffusion is said to be
anisotropic. Anisotropic diffusion in the brain is due to underlying tissue anisotropy, with
both myelin and axons contributing to the restriction of the free diffusion of water. Diffusion
anisotropy is typically represented by an anisotropy index such as the fractional anisotropy
(FA), the fraction of the “magnitude” of the diffusion along the principal axis of the
diffusion tensor (Pierpaoli and Basser 1996). FA has been used as a marker for white matter
tract integrity (Bammer et al. 2000; Filippi et al. 2001; Werring et al. 1999), reflecting the
state of inflammation or myelination. Furthermore, it has been proposed that changes in the
eigenvalues of the diffusion tensor may reflect either demyelination or axonal damage
(Budde et al. 2009; Song et al. 2003).
Multiple sclerosis relapses decrease during late pregnancy and increase after birth, when
female sex hormones are at high and low levels, respectively (Birk et al. 1990; Confavreux
et al. 1998), suggesting a protective role (Voskuhl 2003). In EAE, both estriol and estradiol
have been shown to be protective (Bebo et al. 2001; Jansson et al. 1994; Kim et al. 1999;
Liu et al. 2003; Palaszynski et al. 2004; Papenfuss et al. 2011; Polanczyk et al. 2004).
Numerous anti-inflammatory mechanisms appear to underlie the protective effect of
estrogen in EAE (Ito et al. 2001; Subramanian et al. 2003; Zang et al. 2002). Further, work
by our group has suggested a direct neuroprotective role for estrogens independent of these
anti-inflammatory effects (Crawford et al. 2010; Spence et al. 2011; Tiwari-Woodruff et al.
2007).
The actions of estrogen are mediated primarily by nuclear estrogen receptors ER-alpha and
ER-beta, although non-genomic membrane effects have also been described (Weiss and
Gurpide 1988). Among the unresolved issues in the use of estrogens as neuroprotective
agents are whether neuroprotective effects are primary, direct effects within the CNS, or
secondary, indirect effects reducing inflammation into the CNS. While in most neurological
disease models the protective effect of estrogen treatment has been shown to be mediated
through ER-alpha and has been associated with anti-inflammatory effects (Merchenthaler et
al. 2004; Morales et al. 2006; Suzuki et al. 2007; Suzuki et al. 2006), these are not mutually
exclusive of direct neuroprotective mechanisms. In EAE, ER-alpha ligand treatment
preserved myelin and neuronal staining while reducing inflammation in spinal cords,
whereas ER-beta ligand treatment preserved myelin and neuronal staining without reducing
inflammation (Tiwari-Woodruff et al. 2007). How these two similar, but distinct,
neuroprotective treatments might influence the imaging outcomes of gray matter atrophy
and diffusion anisotropy is unknown. Thus, the purpose of this study was to contrast the
effects of EAE on gray matter atrophy and diffusion anisotropy in ER-alpha versus ER-beta
ligand-treated EAE mice.
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MATERIALS AND METHODS
Mice
Female C57BL/6 mice, 6 weeks old, were purchased from the Jackson Laboratory. All
studies were performed in accordance with approval from the UCLA Office of Protection of
Research Subjects.
Reagents
Estradiol (E2) was purchased from Sigma-Aldrich (St. Louis, MO). Propylpyrazole triol
(ER-alpha ligand) and diarylpropionitrile (ER-beta ligand) were purchased from Tocris
Bioscience (Ellisville, MO). Miglyol 812 N liquid oil was obtained from Sasol North
America (Houston, TX). Myelin oligodendrocyte glycoprotein (MOG) peptide 35–55 was
purchased at greater than 98% purity (Chiron Mimotopes, Emeryville, CA).
Animal Protocol
To remove the confound of endogenous circulating estrogens prior to estrogen treatment,
female mice were ovariectomized following ketamine (100 mg/kg)/xylazine (10 mg/kg)
anesthesia. The fur above the lateral dorsal back was removed and sterilized with betadine
and alcohol scrubs. Bilateral incisions were made into the peritoneum. Sutures were placed
on the fallopian tubes and the ovaries were removed. The peritoneal cavity and the
abdominal musculature were sutured. The skin was secured with wound clips. Flunixin
meglumine (2.5 mg/kg) was injected s.c. every 12 h for 2 days for pain. Enrofloxacin was
added to the water for 5 days following surgery (45.4 mg/125 ml of water). Wound clips
were removed 8–10 days following surgery.
The mice were allowed to recuperate for 10 days and then injected every other day with
vehicle (10% ethanol and 90% miglyol) alone, E2, ER-alpha ligand or ER-beta ligand 7
days prior to EAE induction. E2, ER-alpha ligand and ER-beta ligand were dissolved in
vehicle to give the final proper concentration of 0.04 mg/kg/d E2 (Jansson et al. 1994), 10
mg/kg/d ER-alpha ligand (Harris et al. 2002) and 8 mg/kg/d ER-beta ligand (Carswell et al.
2004). E2, ER-alpha ligand, ER-beta ligand or vehicle alone were given by daily
subcutaneous injections along the midbackline and continued for the entire disease duration
(up to 69 days after disease induction).
Experimental Autoimmune Encephalomyelitis
Mice were immunized with MOG peptide 35–55 (300 µg/mouse) and Mycobacterium
tuberculosis (500 µg/mouse) emulsified in Complete Freund’s Adjuvant subcutaneously, in a
volume of 0.1 ml/mouse over two sites: the right draining inguinal and axillary lymph
nodes. One week later a booster immunization was delivered subcutaneously, over the
contralateral draining lymph nodes. Pertussis toxin (500 ng/mouse) (List Biological
Laboratories, Inc., Campbell, CA) was injected intraperitoneally on days 0 and 2 (Liu et al.
2003; Suen et al. 1997). EAE was graded on a scale of 0 to 5, based on difficulty with
ambulation, as described (Pettinelli and McFarlin 1981). A total of four independent EAE
groups were used in this study.
Sample Preparation
Mice were anesthetized deeply using isofluorane. The mouse was then fixed by transcardiac
perfusion using 30 ml of phosphate buffered saline (PBS) followed by 30 ml 4%
paraformaldehyde (PFA) at 4°C. After death, the head was removed and rocked in 4% PFA
overnight at 4°C. Soft tissue was removed and the skull (containing the brain) was rocked in
50 ml 0.01% sodium azide in PBS for 7.0 days at 4°C. The skull was then transferred to a 5
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mM solution of gadoteridol (Prohance, Bracco Diagnostics Inc., Princeton NJ) and 0.01%
sodium azide in PBS and rocked for 15 days at 4°C prior to MR imaging. Equilibration of
the fixed brain in 5 mM gadoteridol solution significantly reduces the T1 of the sample and
therefore reduces the total imaging time for a given resolution and target signal-to-noise
ratio. All brains were equilibrated at room temperature for 8 hours immediately prior to
imaging at 20°C.
Magnetic resonance imaging
All images were acquired using a vertical bore 11.7 T Bruker Avance DRX500 system
(Bruker Biospin, Germany) equipped with a Micro2.5 imaging gradient set capable of a
peak gradient strength of 1 T/m and a maximum slew rate of 12.5 kT/m/s. The skull
(containing the brain) was secured in a Teflon holder and submerged in a perfluoropolyether
(Fomblin, Solvay Solexis, Inc., Thorofare, NJ) within a 20 ml vial and imaged using a 35
mm birdcage transmit/receive volume resonator. All samples were equilibrated at room
temperature prior to imaging. The ambient bore temperature was maintained at 20°C by
thermostatically controlled airflow. Optimized second order shimming was achieved across
the whole sample using the Bruker implementation of Fastmap (Gruetter 1993).
Diffusion-weighted images were acquired using a conventional pulsed-gradient spin echo
(PGSE) sequence (TR/TE = 150 ms/11.6 ms, 256 × 150 × 130 matrix, 19.2 mm × 15 mm ×
12 mm FOV, 80 Am isotropic voxel size, 1 average, diffusion gradient length: δ = 3 ms,
diffusion gradient separation: Δ = 5 ms, diffusion gradient magnitude: Gd = 750 mT/m,
nominal b-factor = 1450 s/mm2). An optimized six point icosahedral encoding scheme
(Hasan et al. 2001) was used for diffusion-weighted acquisitions with a single unweighted
reference image for a total imaging time of 6 h.
Image Processing
Image processing was performed using a combination of freely distributed and in-house
software implemented in Matlab (The Mathworks Inc., Natick MA). Reconstruction of the
diffusion-weighted images included spatial radial Gaussian filtering (radial SD = 0.25 voxel)
to smooth the coregistration cost-function and improve the SNR of all subsequent
calculations. The six diffusion-weighted images were averaged to generate a high SNR
isotropic diffusion-weighted image (iDWI) which could be used for both brain segmentation
and image coregistration.
The apparent diffusion tensor was calculated conventionally by inversion of the encoding b-
matrix (Mori 2007). Small shifts and rotations of the diffusion-weighted images were
observed and ascribed to residual eddy currents from the high-amplitude diffusion encoding
pulses persisting through the echo acquisition. Diffusion-weighted images were
consequently registered to the diffusion unweighted image using a rigid-body transform
under the assumption that the original diffusion encoding directions were exact and that the
unweighted image best represents the true orientation of the mouse brain relative to the
imaging gradient axes. The b-matrix for each diffusion encoding was determined by
numerical simulation of the pulse sequence k-space trajectory in order to account for
gradient cross-terms (Mattiello et al. 1997). Eigenvalues, eigenvectors, tensor trace and
fractional anisotropy were calculated conventionally using built-in and custom Matlab
functions.
iDWIs were skull-stripped using the Brain Surface Extractor (BSE) within BrainSuite 2
(Shattuck and Leahy 2001). Inaccuracies were corrected by manually editing the masks
using BrainSuite 2. After skull-stripping, field inhomogeneities were corrected using N3
correction (Sled et al. 1998). A minimum deformation target (MDT) was produced as
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described (Kochunov et al. 2001). Each of the images was then linearly aligned to the MDT
with a 12-parameter full-affine transformation using Alignlinear (AIR 5.2.5) (Woods et al.
1998a; Woods et al. 1998b) and the least squares with intensity rescaling cost function
followed by a 5th-order polynomial warp using Align_warp (AIR). The images were then
resampled and averaged to produce the final minimum deformation atlas (MDA). The MDA
was then aligned to a standard atlas (MacKenzie-Graham et al. 2004) to permit the direct
comparison of images in a standard space. Automated image processing was performed in
the LONI Pipeline Processing Environment (Rex et al. 2003) using a 8-processor Mac Pro
computer (Apple Inc., Cupertino, CA).
Anatomical Delineations
A blinded expert neuroanatomist using BrainSuite 2 manually delineated anatomical
structures on the MDA. Anatomical delineations included cerebellar cortex, cerebellar white
matter, and olfactory bulb. Cerebellar cortex delineations rigorously excluded white matter
and partial volume voxels. Anatomical delineations were based on the Mouse Atlas Project
2003 mouse brain atlas (MacKenzie-Graham et al. 2004) and assisted by the The Mouse
Brain in Stereotaxic Coordinates 3rd edition (Franklin and Paxinos 2008).
Image Analysis
Images were spatially normalized with a 12-parameter full-affine transformation to register
each image to the MDA using Alignlinear (AIR). In order to intensity normalize the images
the alignment was performed with an intensity rescaling cost function. Align_warp (AIR)
was used to compute 5th-order polynomial mappings of the MDA to each individual
normalized brain. These mappings were then used to warp the anatomical delineations from
the MDA to each of the individual images making up the atlas. Individual delineations were
manually corrected and volumes recorded using BrainSuite 2.
Mean fractional anisotropy measurements were made by averaging the voxel values that
were enclosed by the cerebellar white matter delineation using built-in and custom Matlab
functions.
Tissue Preparation
After imaging, brains were removed from the skull and prepared for sectioning. 50 µm thick
sagittal frozen sections were cut using a CM3050S cryostat (Leica Microsystems, Wetzlar,
Germany). Free-floating sections were permeabilized in 0.3% Triton X-100 in PBS and
blocked with 10% normal goat serum (Vector Laboratories, Burlingame, CA). White matter
immunostaining was enhanced by treating sections with 95% ethanol/5% acetic acid for 15
minutes prior to permeabilization and blocking. Sections were incubated with primary
antibodies in PBS solution containing 2% NGS for 2 hours at room temperature, then
overnight at 4°C. The following primary antibodies were used: mouse anti-beta amyloid
precursor protein (1:500; Abcam, Cambridge, MA), mouse anti-calbindin-2 (1:500; Sigma-
Aldrich), rat anti-CD3 (1:1000; Millipore, Billerica, MA), rat anti-CD45 (1:1000;
Millipore), rabbit anti-IBA-1 (1:1000; Wako, Richmond, VA), and rat anti-myelin basic
protein (1:500; Millipore).
Fluorescence secondary antibody labeling included antibodies conjugated to Cy3 and Cy5
(Millipore). To assess the number of cells, 4',6'-diamidino-2-phenylindole dihydrochloride
(DAPI; Invitrogen, Carlsbad, CA) was added for 15 minutes prior to final washes after
secondary antibody addition. The sections were mounted on slides, dried, and coverslipped
with fluoromount G (Fisher Scientific).
MacKenzie-Graham et al. Page 5
J Neurosci Res. Author manuscript; available in PMC 2013 July 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Chromogen immunohistochemistry was performed, after avidin-biotin block, by incubating
with a biotinylated secondary antibody. A streptavidin-peroxidase conjugate was added,
followed by the addition of 3,3'-diaminobenzidine (DAB; Vector Laboratories). The sections
were mounted, dehydrated and coverslipped with Permount (Fisher Scientific, Pittsburgh,
PA).
IgG-control experiments were performed for all primary antibodies, and no staining was
observed under these conditions.
Microscopy and Analysis
Confocal images of immunostained sections were photographed using a spin-disc (Olympus,
Center Valley, PA) and TCS-SP laser confocal microscope (Leica Microsystems) with a
digital camera (Hamamatsu Photonics, Bridgewater, NJ). All images were collected using
similar acquisition parameters. Photomicrographs of each representative experimental group
were collected and analyzed with ImageJ software (v1.45a).
The degree of axonal damage, demyelination, and inflammation in cerebellar white and gray
matter was assessed by quantifying anti-beta-APP, anti-MBP, and anti-CD45 staining by
optical density. Confocal stacks of immunolabeled images from each animal were processed
with a series of manual and automated procedures that included the following steps: (1) the
images were oriented in the same direction, (2) the RGB channels of the images were split
and converted to 8 bit gray images in Image J, (3) gray matter (granule cell, Purkinje cell
and molecular layers) and white matter was manually delineated on the basis of DAPI
staining, and (4) threshold gray matter and white matter density was calculated and reported
as a percentage of total area.
Macrophages and microglia (IBA-1+), T-lymphocytes (CD3+) and Purkinje cells
(calbindin-2+), were quantified by counting cell bodies in 10X images of the entire
cerebellum. Dehydration in chromogen-stained sections does not permit many z-planes to be
available, so here we counted cells in a projected image. Three to five brain sections (50 µm
thick) 200 µm apart were analyzed from each animal (ovarectomized vehicle-treated healthy
controls: n = 5; ovarectomized vehicle-treated EAE mice: n = 5; ovarectomized ER-alpha
ligand-treated EAE mice: n = 3; ovarectomized ER-beta ligand-treated EAE: n = 4). All
sections counted were close to midline. Only cells with their entire nucleus present in the
section were counted. Some of the animals imaged were excluded from the analysis due to
incomplete perfusion or because the tissue was damaged.
Statistics
All results are presented as mean ± standard error of the mean (SEM) and statistical
differences were determined by the Welch’s t-test. ANOVAs and Welch’s t-tests were
performed in Excel (Microsoft, Redmond, WA). Comparisons were subject to post hoc
multiple comparisons confounds, so the results of the Bonferroni correction (p < α/n) were
considered.
RESULTS
Post-mortem diffusion tensor imaging (DTI) scans were acquired from 30 female mice: 5
unmanipulated healthy controls, 5 ovarectomized vehicle-treated healthy controls, 5
ovarectomized vehicle-treated EAE mice, 5 ovarectomized ER-alpha ligand-treated EAE
mice, 5 ovarectomized ER-beta ligand-treated EAE mice and 5 ovarectomized E2-treated
EAE mice (as a positive control for estrogen treatment). The mice were sacrificed 69 days
after disease induction (Fig. 1). There was a significant difference in the disease course
between the ER-beta ligand-treated EAE mice and both the ER-alpha ligand- and E2-treated
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EAE mice. Specifically, treatment with ER-alpha ligand and E2 completely blocked the
entire disease course at both early and late time-points, while ER-beta ligand treatment only
ameliorated disease late, but not early, consistent with previous reports (Gold et al. 2009;
Tiwari-Woodruff et al. 2007; Tiwari-Woodruff and Voskuhl 2009).
A minimum deformation atlas (MDA) was constructed from the 30 isotropic diffusion-
weighted images derived from the DT images collected (Fig. 2). The MDA then served as a
target space for the spatial and intensity normalization of the original images, correcting
both gross size and intensity differences. Following creation of this atlas, the olfactory
bulbs, cerebellar cortices and cerebellar white matter were manually delineated on that atlas.
The delineations were then warped onto the normalized images to produce standardized
estimates of gray matter volumes in individual subjects.
Estrogen receptor ligand treatment of mice with EAE inhibits atrophy in the cerebellar
cortex
We have previously demonstrated cerebellar atrophy in mice with EAE (MacKenzie-
Graham et al. 2006; MacKenzie-Graham et al. 2009), an observation that has also been
made in MS (Edwards et al. 1999; Iannucci et al. 1999; Liu et al. 1999). Our group has also
demonstrated that estrogen-mediated disease protection in EAE may be due not only to the
anti-inflammatory effects of estrogen, but also due to its neuroprotective properties which
can be independent of reducing inflammation (Spence et al. 2011; Tiwari-Woodruff et al.
2007). Specifically, ER-alpha ligand treatment during EAE ameliorates clinical disease
while reducing white matter inflammation in spinal cords, while ER-beta ligand treatment
ameliorates clinical disease while not reducing inflammation. Therefore, using the
methodology previously described to evaluate gray matter atrophy in mice with EAE
(MacKenzie-Graham et al. 2009), we measured cerebellar cortical volumes in EAE mice
that had been treated with vehicle, ER-alpha ligand or ER-beta ligand and compared them to
healthy controls (Fig. 3). The volumes of the cerebellar cortices in the unmanipulated and
ovarectomized healthy controls were not significantly different (data not shown). However,
ovarectomized vehicle-treated EAE mice demonstrated an 8.4% decrease in the size of
cerebellar cortex compared to ovarectomized vehicle-treated healthy controls (p = 0.002).
ER-alpha ligand-treated (p = 0.00009), ER-beta ligand-treated (p = 0.003) or E2-treated (p =
0.006) EAE mice had cerebellar cortices that were significantly larger than vehicle-treated
EAE mice and were not significantly different than those in vehicle-treated healthy controls.
The volume of a control structure, the olfactory bulb, did not vary significantly in any of the
groups. These data demonstrate that regardless of whether a given estrogen receptor ligand
can reduce CNS inflammation, they each can prevent cerebellar cortical atrophy in EAE.
Estrogen receptor ligand treatment of mice with EAE inhibits Purkinje cell loss
In previous work we demonstrated cerebellar atrophy in mice with EAE over time
(MacKenzie-Graham et al. 2006) and that a loss of Purkinje cells in EAE correlated strongly
with that atrophy (MacKenzie-Graham et al. 2009). Furthermore, ER-alpha expression has
been shown in the cerebellum (Shughrue et al. 1997; Simerly et al. 1990), specifically in
Purkinje cells (Ikeda and Nagai 2006), and ER-beta has been shown to be expressed in the
Purkinje cells (Jakab et al. 2001; Price and Handa 2000; Shughrue et al. 1997). Thus, we
hypothesized that estrogen-mediated disease protection in mice with EAE might be due to
not only the effects on inflammation and demyelination, but also due to the preservation of
Purkinje cells in the cerebellum. This may in turn be associated with a prevention of
cerebellar atrophy.
Calbindin-2 immunostaining demonstrated a disruption of the normal anatomy of the
Purkinje and molecular layers of the cerebellar cortex in vehicle-treated EAE mice
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compared to E2-treated EAE mice, ER-alpha ligand-treated EAE mice, ER-beta ligand-
treated EAE mice and healthy controls (Fig. 4). Purkinje cell numbers were found to be
17.7% lower in vehicle-treated EAE mice than healthy controls (p = 0.02) (Fig. 5). Purkinje
cell numbers were significantly greater in E2 and ER-alpha ligand-treated EAE mice as
compared to vehicle-treated EAE mice (p = 0.02, p = 0.002), and were not significantly
different from healthy controls. Purkinje cell numbers were also significantly preserved in
ER-beta ligand-treated EAE mice as compared to vehicle-treated EAE mice (p = 0.004).
Together these neuroimaging and neuropathological results suggest that gray matter atrophy
as measured by MRI morphometry may be a biomarker for neuronal cell loss in EAE.
Fractional anisotropy is reduced in vehicle-treated and ER-beta ligand-treated, but not in
estradiol-treated or ER-alpha ligand-treated mice with EAE
Fractional anisotropy has previously been used as a marker for white matter tract integrity
(Bammer et al. 2000; Filippi et al. 2001; Werring et al. 1999). In order to evaluate white
matter tract integrity, we measured the mean FA in the cerebellar white matter of mice with
EAE that had been treated with vehicle only, E2, ER-alpha ligand or ER-beta ligand and
compared them to healthy controls (Fig. 6). Vehicle-treated EAE mice demonstrated an
9.1% decrease in the FA of cerebellar white matter compared to controls (p = 0.00001). FA
was significantly higher in ER-alpha ligand-treated (p = 0.00006) and E2-treated EAE mice
(p = 0.0004) as compared to vehicle-treated EAE mice, and was not significantly different
from healthy controls (Fig. 7). However, ER-beta ligand-treated EAE mice were not
significantly different from vehicle-treated EAE mice, demonstrating an 8.0% decrease in
FA as compared to controls (p = 0.00004). Together these neuroimaging and
neuropathological results demonstrate that the treatment effects of atrophy versus FA may
differ during EAE.
Estrogen receptor ligand treatment of mice with EAE preserves myelin in the cerebellum
Changes in fractional anisotropy may be due to changes in myelination. Thus, to further
investigate differences observed in the FA of the cerebellar white matter in these mice, we
measured myelin basic protein (MBP) expression. MBP immunoreactivity was measured to
explore the state of myelin in both white and gray matter in the cerebellum. Healthy control
tissue showed dense MBP staining in the central white matter tracts, with regular, parallel
arrays of myelinated axons radiating into the granule cell layer (Fig. 8). White matter
myelination was substantially greater than gray matter myelination. Quantification indicated
that white and gray matter MBP immunoreactivity was significantly lower in vehicle-treated
EAE mice than healthy controls (p = 0.01, p = 0.0004) (Fig. 9). White and gray matter MBP
immunoreactivity was significantly greater in E2-treated EAE mice as compared to vehicle-
treated EAE mice (p = 0.0005, p = 0.008), and not significantly different from healthy
controls. Similarly, white and gray matter MBP immunoreactivity was significantly greater
in ER-alpha ligand-treated EAE mice as compared to vehicle-treated EAE mice (p = 0.006,
p = 0.0006), and not significantly different from healthy controls. Interestingly, white and
gray matter MBP immunoreactivity was also significantly preserved in ER-beta ligand-
treated EAE mice as compared to vehicle-treated EAE mice (p = 0.01, p = 0.006). The
preservation of myelin staining in ER-beta ligand-treated mice who had a significant
decrease in FA suggested that a neuropathology other than demyelination was underlying
the decrease in FA.
Cerebellar inflammation in EAE is decreased with ER-alpha ligand, but not in ER-beta
ligand treatment
Previous studies have shown that changes in FA can be caused not only by demyelination
but also by inflammation. Thus, we next focussed our neuropathological analysis of the
cerebella of mice with EAE on inflammation. Protein tyrosine phosphatase, receptor type C
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(CD45) immunoreactivity is a commonly used measure of inflammation. Therefore, CD45
immunoreactivity was measured to explore the state of inflammation in both white and gray
matter in the cerebellum. Healthy control tissue showed very little CD45 staining in either
the white or gray matter (Fig. 10). Quantification indicated that white and gray matter CD45
immunoreactivity was significantly higher in vehicle-treated EAE mice as compared to
healthy controls (p = 0.00005, p = 0.001) (Fig. 11A & B). White and gray matter CD45
immunoreactivity was significantly decreased in E2-treated as compared to vehicle-treated
EAE mice (p = 0.001, p = 0.00002), and not significantly different from healthy controls.
Similarly, white and gray matter CD45 immunoreactivity was significantly decreased in ER-
alpha ligand-treated as compared to vehicle-treated EAE mice (p = 0.001, p = 0.00002), but
not significantly different from healthy controls. In contrast, ER-beta ligand-treated EAE
mice were not significantly different from vehicle-treated EAE mice, and demonstrated a
significant increase in white and gray matter CD45 immunoreactivity as compared to
healthy controls (p = 0.0001, p = 0.0001).
In order to better characterize the inflammatory response, we next stained with antibodies to
ionized calcium binding adaptor molecule 1 (IBA1) and T-cell co-receptor (CD3). Anti-
IBA1 stains cells of the macrophage/microglia lineage while anti-CD3 stains T-
lymphocytes. IBA1+ cell numbers were significantly higher in vehicle-treated EAE mice
than healthy controls in both white and gray matter (p = 0.000003, p = 0.00004) (Fig. 11C &
D). IBA1+ cell numbers in white and gray matter were significantly lower in E2-treated
EAE mice as compared to vehicle-treated EAE mice (p = 0.000003, p = 0.00004), and not
significantly different from healthy controls. Similarly, IBA1+ cell numbers in white and
gray matter were significantly lower in ER-alpha ligand-treated EAE mice as compared to
vehicle-treated EAE mice (p = 0.000003, p = 0.00003), and not significantly different from
healthy controls. In contrast, ER-beta ligand-treated EAE mice were not significantly
different from vehicle-treated EAE mice, and demonstrated significantly greater IBA1+ cell
numbers as compared to controls (p = 0.000002, p = 0.00004).
Quantification of CD3+ staining indicated that T-lymphocyte numbers in white and gray
matter were significantly higher in vehicle-treated EAE mice than healthy controls (p =
0.000005, p = 0.00001) (Fig. 11E & F). CD3+ cell numbers in white and gray matter were
significantly lower in E2-treated EAE mice as compared to vehicle-treated EAE mice (p =
0.000005, p = 0.00003), and not significantly different from controls. Similarly, CD3+ cell
numbers in white and gray matter were significantly lower in ER-alpha ligand-treated EAE
mice as compared to vehicle-treated EAE mice (p = 0.000005, p = 0.00003), and not
significantly different from controls. However, ER-beta ligand-treated EAE mice were not
significantly different from vehicle-treated EAE mice, and demonstrated significantly higher
CD3+ cell numbers as compared to controls (p = 0.000003, p = 0.00001). There was no
significant difference in CD3+ cell number between vehicle-treated and ER-beta ligand-
treated EAE mice.
Estrogen receptor ligand treatment of mice with EAE abrogates axonal damage in
cerebellar white matter
Another possible cause for changes in fractional anisotropy may be due to axonal damage.
Therefore we measured beta-amyloid precursor protein (beta-APP) expression, a sensitive
marker of axonal injury (Ferguson et al. 1997). Healthy control tissue showed virtually no
beta-APP staining in white matter tracts (Fig. 12). Quantification indicated that beta-APP
immunoreactivity was much higher in vehicle-treated EAE mice than healthy controls (p =
0.0001) (Fig. 13). Beta-APP immunoreactivity was significantly lower in E2- and ER-alpha
ligand-treated EAE mice as compared to vehicle-treated EAE mice (p = 0.0001, p = 0.0001).
Interestingly, beta-APP immunoreactivity was also significantly lower in ER-beta ligand-
treated EAE mice as compared to vehicle-treated EAE mice (p = 0.0002).
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Together these neuroimaging and neuropathological results demonstrate that the ability of a
given treatment to reduce inflammation in a given substructure coincides with its ability to
preserve FA within the same substructure in EAE. These results are summarized in Table 1.
DISCUSSION
Most therapies for MS have been developed to reduce inflammation. Interferon-beta,
glatiramer acetate and mitoxantrone have considerably improved the therapeutic options for
patients with MS. These anti-inflammatory agents reduce relapse rates and reduce the
appearance of contrast-enhancing lesions. However, their efficacy in preventing
accumulation of disability, slowing gray matter atrophy and their impact on disease
progression has been somewhat disappointing (Trojano et al. 2006; Van der Walt et al.
2010).
In this study, we have contrasted effects of treatment with ER-alpha versus ER-beta ligands
on gray matter atrophy in EAE, the MS model with a known pathogenic role for both
inflammation and neurodegeneration. Morphometry demonstrated that atrophy was
abrogated in ER-alpha ligand-, ER-beta ligand- and E2-treated EAE mice. Similarly,
Purkinje cell numbers were preserved in ER-alpha ligand-, ER-beta ligand and E2-treated
EAE mice. Interestingly, the mean fractional anisotropy was preserved in ER-alpha ligand-
and E2-treated EAE mice, but not in ER-beta ligand-treated EAE mice.
Immunohistochemistry demonstrated that white and gray matter myelin staining was
preserved in both ER-alpha ligand-, ER-beta ligand- and E2-treated EAE mice, however,
cerebellar inflammation in EAE was decreased in ER-alpha ligand- and E2-treated, but not
in ER-beta ligand-treated EAE mice. Together, we have demonstrated that DTI can visualize
treatment effects on different elements of the pathology of EAE. Specifically, atrophy is a
biomarker for Purkinje cell number and FA can be used as a biomarker for inflammation in
the cerebellum in EAE. Both proved to be be highly informative in assessing the effects of
treatments on disease.
Since the variability was low in both clinical scores and mean cerebellar cortex volumes
within each treatment group, one could not assess whether mice with worse clinical scores
had more atrophy within a given treatment group. However, between group comparisons
revealed that vehicle-treated mice with EAE indeed had both worse clinical scores and more
atrophy than E2-, ER-alpha ligand-, or ER-beta ligand-treated mice with EAE. FA values
were also characterized by low variability within groups. In contrast to cerebellar volumes,
between group comparisons of cerebellar FA did not show an association with disease. This
was principally due to the fact that the ER beta ligand treated group demonstrated disease
amelioration paired with a low FA.
Our results show for the first time that estrogen treatment can prevent gray matter atrophy
and preserve Purkinje cells in the cerebellum during EAE. The prevention of the loss of this
major neuronal cell type in EAE is significant due to their functional relevance. Purkinje
cells are intimately involved in motor activity and represent the only output pathway of the
cerebellar cortex (Parent 1996). The ER-beta ligand treatment effect was clearly not
mediated by a reduction of cerebellar inflammation, since there was no significant difference
in CD45 expression, IBA1+ cell number nor CD3+ cell number between ER-beta ligand-
treated and vehicle-treated EAE mice. What remains unknown is whether the
neuroprotective effect of ER-beta ligand treatment is mediated through binding to ER-beta
receptors on neurons, oligodendrocytes, or astrocytes, because all of these CNS cell types
have been shown to express ER-beta in vivo (Platania et al. 2003). In fact, it is likely that
there is a direct effect of estrogen receptor beta ligand treatment on Purkinje cell survival
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since Purkinje cells have been shown to express estrogen receptor beta (Jakab et al. 2001;
Price and Handa 2000; Sakamoto et al. 2003; Shughrue et al. 1997).
Though our results are strongly suggestive of a direct effect of estrogen on Purkinje cells,
we cannot eliminate the possibility that the estrogen effect is mediated by other cells such as
astrocytes (Spence et al. 2011) or even non-CNS cells. Propyl pyrazole triol (ER-alpha
ligand) and diarylpropionitrile (ER-beta ligand) are estrogen receptor agonists with well
characterized affinities for ER-alpha and ER-beta respectively (Harrington et al. 2003;
Meyers et al. 2001), and previous studies with knockout mice(Morales et al. 2006) have
established the selectivity and responsiveness of these ligands in vivo. Results obtained from
this approach should complement studies with knockout mice and help to further expand our
appreciation of the complexities of estrogen action.
A decrease in FA has previously been reported in dysmyelinating shiverer mice compared to
normal controls thereby suggesting that FA is indicative of the level of myelination (Tyszka
et al. 2006). Our finding that the fractional anisotropy is decreased in mice with EAE was
similarly reported using a related measure, relative anisotropy in EAE (Budde et al. 2009).
Consistent with our results, whereby decreases in FA were independent of myelin staining,
Budde et al. found no correlation between relative anisotropy and MBP staining in EAE
(Budde et al. 2009). Differences between these two reports involve the relationship between
FA and inflammation. Budde et al. demonstrated a weak correlation between relative
anisotropy and cellular infiltrate. In contrast, our findings suggested that decreases in FA are
related to inflammation, since both vehicle- and ER-beta ligand-treated EAE mice
demonstrated a decrease in FA and both vehicle- and ER-beta ligand-treated EAE mice
demonstrated increased inflammatory cell infiltration. One possible explanation for the
discrepancy in our findings could be differences in staining. We stained for very specific
markers of inflammation (CD45, CD3 and IBA1), whereas Budde et al. used a non-specific
nuclear stain (DAPI+) to measure inflammation indirectly. Second, and perhaps more
importantly, we evaluated FA in the cerebellar white matter, while Budde et al. evaluated
white matter tracts of the spinal cord. The diffusion anisotropy in the cerebellar white matter
is lower than in the white matter tracts of the spinal cord in normals. The cerebellar white
matter contains many white matter tracts traveling in different directions; it is comprised of
the cerebellodentatorubral, cerebellodentatothallamic, cerebellovestibular, cuneocerebellar,
olivocerebellar, pontocerebellar, reticulcerebellar, spinocerebellar, trigeminocerebellar and
vestibulospinal fiber tracts, not to mention the myelinated Purkinje cell axons that project to
the deep cerebellar nuclei. It is possible that the FA in the white matter in the cerebellum is
more sensitive to inflammation than in the highly organized spinal cord. Lastly, we
calculated the mean FA for the entire cerebellar white matter and counted infiltrating cells
across the entire cerebellum, whereas Budde et al. focussed on specific areas of the spinal
cord and evaluated their correlations on a pixel-by-pixel basis. Together these findings
suggest that FA may be a sensitive biomarker for inflammation depending on the CNS area
of study.
In an effort to better understand the pathology in MS lesions, DTI has proven to be a
valuable tool. Anisotropy measures have commonly been used as biomarkers for
demyelination and axonal damage. For example, decreased FA has been shown to be more
pronounced in lesions than in the normal appearing white matter (NAWM); though its
values are highly heterogeneous. This has been interpreted as indicating the variable degrees
of tissue damage occurring within MS lesions (Filippi et al. 2001). However, FA is always
lower in contrast-enhancing lesions, especially ring-enhancing lesions (Bammer et al. 2000),
as compared to non-enhancing lesions, the latter of which are thought to reflect
demyelination and axonal damage with minimal inflammatory infiltrate (Castriota-
Scanderbeg et al. 2003; Filippi et al. 2001). Contrast enhancement is thought to be due to
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blood–brain barrier breakdown secondary to inflammatory cell infiltration. Histological
studies lend support to this idea, demonstrating that lesions with enhancement show
inflammatory activity, either macrophage infiltration (Nesbit et al. 1991) or perivascular
lymphocytic infiltration (Katz et al. 1993). Our findings demonstrate that inflammation can
play an important role in the decrease of FA in the white matter of mice with EAE and
suggests that the use of decreased FA as a biomarker for demyelination and axonal damage
(Hesseltine et al. 2006) should be tempered with the understanding that inflammation may
be playing a major role in the observed decrease.
In summary, we have found that treatment of mice with EAE with either estrogen receptor
alpha or estrogen receptor beta ligand prevents gray matter atrophy and preserves a major
neuronal population. This finding has implications for treatment in MS, suggesting that early
treatment with neuroprotective agents may help spare patients from permanent clinical
disability and irreversible neuronal damage. Further, multimodal approaches using
neuroimaging combined with immunohistochemistry in disease models suggests that DTI
can indeed differentiate between different treatment mechanisms.
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Fig. 1.
Clinical disease course. A graph of the mean clinical disease score in mice with EAE plotted
against disease duration. Each color represents a treatment group (red for vehicle-treated
EAE mice (EAE), green for estradiol-treated EAE mice (E2), blue for ER-alpha ligand-
treated EAE mice (ERa) and yellow for ER-beta ligand-treated EAE mice (ERb); for clarity
colors are alternated when lines are overlaid) and is used consistently in subsequent figures.
Error bars indicate SEM.
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Fig. 2.
Minimum deformation atlas and delineations. A minimum deformation atlas was
constructed from 30 postmortem high-resolution isotropic diffusion-weighted images of
mouse brain. The anatomical delineations of the cerebellar cortex (red) and cerebellar white
matter (yellow) are overlaid on the image. Scale bar = 5 mm.
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Fig. 3.
Estrogen receptor ligand treatment of mice with EAE inhibits atrophy in the cerebellar
cortex. A graph of the mean cerebellar cortical volume in ovarectomized vehicle-treated
healthy controls (CON), ovarectomized vehicle-treated EAE mice (EAE), ovarectomized
estradiol-treated EAE mice (E2), ovarectomized ER-alpha ligand-treated EAE mice (ERa)
and ovarectomized ER-beta ligand-treated EAE mice (ERb). Error bars indicate SEM.
Asterisks indicate statistical significance (* p < 0.01, ** p < 0.0001). All significant
differences survive the application of the Bonferroni correction for post hoc testing.
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Fig. 4.
Purkinje cell staining in the cerebellum. Calbindin-28K immunostained confocal images at
10X magnification from the cerebellum of an ovarectomized vehicle-treated healthy control
mouse (A), an ovarectomized vehicle-treated mouse with EAE (B), an ovarectomized E2-
treated mouse with EAE (C), an ovarectomized ER-alpha ligand-treated mouse with EAE
(D) and an ovarectomized ER-beta ligand-treated mouse with EAE (E). Scale bar = 80 um.
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Fig. 5.
Estrogen receptor ligand treatment of mice with EAE inhibits Purkinje cell loss. A graph of
the number of calbindin-2+ cells in the cerebella of ovarectomized vehicle-treated healthy
controls (CON), ovarectomized vehicle-treated EAE mice (EAE), ovarectomized E2-treated
EAE mice (E2), ovarectomized ER-alpha ligand-treated EAE mice (ERa) and
ovarectomized ER-beta ligand-treated EAE mice (ERb). Error bars indicate SEM. Asterisks
indicate statistical significance (* p < 0.01, ** p < 0.001, *** p < 0.0001, **** p > 0.00001).
All significant differences survive the application of the Bonferroni correction for post hoc
testing.
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Fig. 6.
Fractional anisotropy in the cerebellum. Fractional anisotropy images derived from diffusion
tensor images of the cerebellum of an ovarectomized vehicle-treated healthy control mouse
(A), an ovarectomized vehicle-treated mouse with EAE (B), an ovarectomized E2-treated
mouse with EAE (C), an ovarectomized ER-alpha ligand-treated mouse with EAE (D) and
an ovarectomized ER-beta ligand-treated mouse with EAE (E). The anatomical delineations
of the cerebellar cortex (magenta) and cerebellar white matter (yellow) are overlaid on the
image. Scale bar = 5 mm.
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Fig. 7.
Fractional anisotropy is reduced in vehicle-treated and ER-beta ligand-treated, but not in
estradiol-treated or ER-alpha ligand-treated mice with EAE. A graph of the mean fractional
anisotropy in the cerebellar white matter of ovarectomized vehicle-treated healthy controls
(CON), ovarectomized vehicle-treated EAE mice (EAE), ovarectomized estradiol-treated
EAE mice (E2), ovarectomized ER-alpha ligand-treated EAE mice (ERa) and
ovarectomized ER-beta ligand-treated EAE mice (ERb). Error bars indicate SEM. Asterisks
indicate statistical significance (* p < 0.01, ** p < 0.001, *** p < 0.0001, **** p > 0.00001).
All significant differences survive the application of the Bonferroni correction for post hoc
testing.
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Fig. 8.
Myelin basic protein staining in the cerebellum. Myelin basic protein immunostained
confocal images at 10X magnification from the cerebellum of an ovarectomized vehicle-
treated healthy control mouse (A), an ovarectomized vehicle-treated EAE mouse (B), an
ovarectomized E2-treated EAE mouse (C), an ovarectomized ER-alpha ligand-treated EAE
mouse (D) and an ovarectomized ER-beta ligand-treated EAE mouse (E). Arrows indicate
demyelinated lesions. Scale bar = 80 um.
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Fig. 9.
Estrogen receptor ligand treatment of mice with EAE preserves myelin staining in the
cerebellum. (A) A graph of the mean myelin-staining in the cerebellar white matter of
ovarectomized vehicle-treated healthy controls (CON), ovarectomized vehicle-treated EAE
mice (EAE), ovarectomized E2-treated EAE mice (E2), ovarectomized ER-alpha ligand-
treated EAE mice (ERa) and ovarectomized ER-beta ligand-treated EAE mice (ERb). (B) A
graph of the mean myelin-staining in the cerebellar gray matter of ovarectomized vehicle-
treated healthy controls (CON), ovarectomized vehicle-treated EAE mice (EAE),
ovarectomized E2-treated EAE mice (E2), ovarectomized ER-alpha ligand-treated EAE
mice (ERa) and ovarectomized ER-beta ligand-treated EAE mice (ERb). Error bars indicate
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SEM. Asterisks indicate statistical significance (* p < 0.01, ** p < 0.001, *** p < 0.0001,
**** p > 0.00001). All significant differences survive the application of the Bonferroni
correction for post hoc testing.
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Fig. 10.
Inflammatory cell staining in the cerebellum. CD45 immunostained confocal images at 4X
magnification from the cerebellum of an ovarectomized vehicle-treated healthy control
mouse (A), an ovarectomized vehicle-treated EAE mouse (B), an ovarectomized E2-treated
EAE mouse (C), an ovarectomized ER-alpha ligand-treated EAE mouse (D) and an
ovarectomized ER-beta ligand-treated EAE mouse (E). Arrows indicate cellular infiltrate.
Scale bar = 200 um.
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Fig. 11.
Inflammation is increased in vehicle-treated and ER-beta ligand-treated, but not in ER-alpha
ligand-treated mice with EAE. (A) A graph of the mean CD45-staining in the cerebellar gray
matter of ovarectomized vehicle-treated healthy controls (CON), ovarectomized vehicle-
treated EAE mice (EAE), ovarectomized E2-treated EAE mice (E2), ovarectomized ER-
alpha ligand-treated EAE mice (ERa) and ovarectomized ER-beta ligand-treated EAE mice
(ERb). (B) A graph of the mean CD45-staining in the cerebellar white matter of
ovarectomized vehicle-treated healthy controls, ovarectomized vehicle-treated EAE mice,
ovarectomized E2-treated EAE mice, ovarectomized ER-alpha ligand-treated EAE mice and
ovarectomized ER-beta ligand-treated EAE mice. (C) A graph of the mean number of
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IBA1+ cells per square mm in the cerebellar white matter of ovarectomized vehicle-treated
healthy controls, ovarectomized vehicle-treated EAE mice, ovarectomized E2-treated EAE
mice, ovarectomized ER-alpha ligand-treated EAE mice and ovarectomized ER-beta ligand-
treated EAE mice. (D) A graph of the number of IBA1+ cells per square mm in the
cerebellar gray matter of ovarectomized vehicle-treated healthy controls, ovarectomized
vehicle-treated EAE mice, ovarectomized E2-treated EAE mice, ovarectomized ER-alpha
ligand-treated EAE mice and ovarectomized ER-beta ligand-treated EAE mice. (E) A graph
of the mean number of CD3+ cells per square mm in the cerebellar white matter of
ovarectomized vehicle-treated healthy controls, ovarectomized vehicle-treated EAE mice,
ovarectomized E2-treated EAE mice, ovarectomized ER-alpha ligand-treated EAE mice and
ovarectomized ER-beta ligand-treated EAE mice. (F) A graph of the number of CD3+ cells
per square mm in the cerebellar gray matter of ovarectomized vehicle-treated healthy
controls, ovarectomized vehicle-treated EAE mice, ovarectomized E2-treated EAE mice,
ovarectomized ER-alpha ligand-treated EAE mice and ovarectomized ER-beta ligand-
treated EAE mice. Error bars indicate SEM. Asterisks indicate statistical significance (* p <
0.01, ** p < 0.001, *** p < 0.0001, **** p > 0.00001). All significant differences survive
the application of the Bonferroni correction for post hoc testing.
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Fig. 12.
Beta-amyloid precursor protein staining in the cerebellum. Beta-APP (red) immunostained
confocal images at 40X magnification from the cerebellum of an ovarectomized vehicle-
treated healthy control mouse (A), an ovarectomized vehicle-treated EAE mouse (B), an
ovarectomized E2-treated EAE mouse (C), an ovarectomized ER-alpha ligand-treated EAE
mouse (D) and an ovarectomized ER-beta ligand-treated EAE mouse (E). Arrows in (B)
indicate lesions centered on blood vessels, whereas the arrow in (E) indicates a blood vessel
without a surrounding lesion. Scale bar = 20 um.
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Fig. 13.
Estrogen receptor ligand treatment of mice with EAE abrogates beta-amyloid precursor
protein staining in the cerebellum. A graph of the mean beta-APP-staining in the cerebellar
white matter of ovarectomized vehicle-treated healthy controls (CON), ovarectomized
vehicle-treated EAE mice (EAE), ovarectomized E2-treated EAE mice (E2), ovarectomized
ER-alpha ligand-treated EAE mice (ERa) and ovarectomized ER-beta ligand-treated EAE
mice (ERb). Error bars indicate SEM. Asterisks indicate statistical significance (* p <
0.0005). All significant differences survive the application of the Bonferroni correction for
post hoc testing.
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